T-cell acute lymphoblastic leukemia
MONDO:0004963Acute lymphoblastic leukemia of T-cell origin. It comprises about 15% of childhood cases and 25% of adult cases. It is more common in males than females. (WHO, 2001)
Also known as: acute T cell leukaemia, T acute lymphoblastic leukaemia, T acute lymphoblastic leukemia, T-ALL, T-cell ALL, T-cell acute lymphoblastic leukaemia, T-cell acute lymphoblastic leukemia, T-cell acute lymphocytic leukemia
2038 clinical trials for this condition and its sub-types, 75 tagged with T-cell acute lymphoblastic leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of T-cell acute lymphoblastic leukemia
-
T-cell prolymphocytic leukemia 17 trials
-
Aggressive NK-cell leukemia 11 trials
-
Double-Barreled immune attack aims to wipe out T-ALL
Disease control Stopped earlyThis early-phase trial tests a two-part immune therapy for people with T-cell acute lymphoblastic leukemia (T-ALL). First, patients receive specially engineered T cells (CAR-T) that target multiple markers on leukemia cells. Then, they get a booster with cytotoxic T cells and a d…
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for tough leukemia: drug combo shows promise in early trial
Disease control Stopped earlyThis study looked at adding a targeted drug called venetoclax to low-intensity chemotherapy for adults with acute lymphoblastic leukemia (ALL) that came back or didn't respond to treatment. The goal was to find the safest dose and see if the combination could help control the dis…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo for tough leukemia shows promise, but trial cut short
Disease control Stopped earlyThis phase 2 trial tested a combination of three drugs—ponatinib, venetoclax, and mini-hyper CVD chemotherapy—in people with relapsed or refractory T-cell acute lymphoblastic leukemia. The goal was to see if the combo could improve remission rates. However, the study was terminat…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Promising combo for tough leukemia stalls: trial ends early
Disease control Stopped earlyThis phase 2 trial tested two drugs, CB-103 and venetoclax, in adolescents and young adults with T-cell acute lymphoblastic leukemia (T-ALL) that had come back or not responded to treatment. The goal was to see if the combination could control the disease. However, the study was …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC